$FDMT

4D Molecular Therapeutics reported positive 2-year results from its phase 2b PRISM trial of 4D-150 for wet age-related macular degeneration. The company said the study showed sustained BCVA and OCT central subfield thickness improvements and reduced treatment burden versus projected on-label aflibercept. Safety was described as well tolerated, with 2.8% mild transient inflammation. Phase 3 topline data is expected in 2027.

4D Molecular Therapeutics (FDMT) shares rose after Phase 2b results for 4D-150 in wet AMD. In 45 patients, the 3E10 vg/eye dose was chosen for Phase 3. As of May 18, 2026, it maintained visual acuity and reduced treatment burden 78% vs projected aflibercept injections, with 2.8% mild inflammation. Phase 3 enrollment completed; topline expected 2027. HC Wainwright reiterated Buy, $36 target.

Kirn David (See Remarks) sold 58,333 shares of 4D Molecular Therapeutics, Inc. (FDMT) at an average of $12.64 ($12.01–$12.87, $0.74M total) across 3 trades over 2026-07-09 to 2026-07-10 under a Rule 10b5-1 trading plan.

4D Molecular Therapeutics, Inc. (FDMT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K false 0001650648 0001650648 2026-06-24 2026-06-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24,

Kirn David (See Remarks) sold 114,746 shares of 4D Molecular Therapeutics, Inc. (FDMT) at $10.47 ($1.20M total) on 2026-06-22 under a Rule 10b5-1 trading plan.

4D Molecular Therapeutics, Inc. (FDMT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001650648 0001650648 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17,

Kirn David (See Remarks) sold 1,922 shares of 4D Molecular Therapeutics, Inc. (FDMT) at $10.02 on 2026-06-01 under a Rule 10b5-1 trading plan.

4D Molecular Therapeutics (Nasdaq: FDMT) said management will present and hold one-on-one meetings at investor conferences in June. It will present at the Jefferies Global Healthcare Conference on June 3, 2026 (3:10 p.m. ET) and at the Goldman Sachs 47th Global Healthcare Conference on June 9, 2026 (2:00 p.m. ET). Archived webcasts will be available on its website for up to a year.

This page from WaterWorld provides the latest news and stock information for 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT). It lists recent company announcements, financial results, clinical trial updates for gene therapies, and participation in investor conferences. The content includes details on stock performance and links to various news sources like MarketBeat, GlobeNewswire, and Benzinga.

This page provides a comprehensive resource for 4D Molecular Therapeutics (FDMT) SEC filings, including annual reports, quarterly earnings, material events, and insider trading forms. It highlights recent Form 8-K filings detailing clinical trial data, collaborations, and executive appointments. The platform also offers AI-powered summaries and sentiment analysis for these regulatory documents.